drugset / Trial / NCT01071928
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the safety and activity of docetaxel + ASA404 as second-line chemotherapy in patients with advanced urothelial carcinoma.
Timeline
- Start
- 2010-06
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASA404 | Unknown | 1800 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |